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Xanthine derivative, pentoxifylline (PTX), has been recently shown to exert a protective effects
in certain animal models of autoimmunity, including diabetes in NOD mice. In the present
study, the immunomodulatory potential of PTX was investigated in autoimmune diabetes
induced by multiple low doses of streptozotocin (MLD-SZ) in genetically susceptible CBA/H
mice (tested with 40 mg SZ/kg b.w. for 5 days) and DA rats (tested with 20 mg/kg b.w. for 5
days). In both species, 2 3 weeks following the MLD-SZ treatment, sustained hyperglycemia
developed, as an outcome of inflammatory reaction with endothelial cell activation and accu-
mulation of mononuclear cells. Although there was no evidence of typical insulitis in early dis-
ease development (day 10), in both rats and mice, macrophages, CD4
/ and CD8
/ cells were
present in the islets of Langerhans as diffuse mononuclear infiltrates with the expression of
IFN-% and inducibleNO synthase (iNOS). Administration ofPTX (200 mg/kg/day for 10 days)
in combination with MLD-SZ reduced insulitis and the production of mediators tested, and pre-
vented the development of hyperglycemia. These results suggest that beneficial effects of PTX
involve down-regulation of local proinflammatory cytokine-mediated NO synthase pathway.
They also demonstrate that in addition to ameliorating spontaneous autoimmunity in NOD
mice, PTX may be effective in downregulating an inflammatory autoimmune process triggered
in susceptible host by an external agents, such as streptozotocin.
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INTRODUCTION
Pentoxifylline (PTX) [3,7-dimethyl-l-(5-oxohexyl)
xanthine] is the drug that is widely used for the treat-
ment of vascular disorders. However, there are new
evidences for the potential therapeutic properties of this
compound. Preclinical studies in laboratory rodents
have shown that PTX and related compounds may
favorably influence the course of experimental inflam-
matory and autoimmune disorders, such as autoim-
mune encephalomyelitis (Rott et al., 1993; Nataf et al.,
1993), meningitis (Saez-Lorens et al., 1990) and
autoimmune neuritis (Constantinescu et al., 1996).
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Insulin-dependent diabetes mellitus is character-
ized by a failure of self-tolerance leading to Thl cell
mediated autoimmune attack leading to destruction of
insulin-producing cells located in the islets of Lang-
erhans. While high doses of -cell toxin streptozo-
tocin (SZ) induce diabetes through a direct toxic
effect on 13-cells, multiple low doses in susceptible
strains of mice and rats initiate an autoimmune
destructive process similar to that observed in human
disease (Like and Rossini, 1976; Luki et al., 1991a;
Kolb and Kroncke, 1993). Therefore, MLD-SZ
induced diabetes allows for the study on agents poten-
tially designed to modulate -cell specific autode-
structive process. However, it is not known whether
there are any differences or similarities between spon-
taneously and experimentally induced diabetic animal
models in the mode of action of different immu-
nomodulatory drugs. Recently Liang et al (1998) have
demonstrated that PTX inhibits secretion of IL-12 by
macrophages and IFN-7 by Thl cells. It appeared that
this effect may be responsible for the amelioration of
insulitis in NOD mice (Liang et al., 1998). Our data
therefore strengthen the notion that similar effector
mechanisms are operative in spontaneous and toxin
induced autoimmune diabetes. By using the model of
diabetes induced by MLD-SZ we demonstrated that
PTX, similarly to spontaneous models of diabetes
(Liang et al., 1998), suppresses development of
hyperglycemia mainly by downregulating the devel-
opment of inflammatory lesions in the pancreata.
RESULTS
Effects ofPTX on Hyperglycemia
In order to evaluate the ability of PTX to interfere
with diabetogenic process induced by an external
agents, streptozotocin, we used both murine and rat
model of autoimmune diabetes induction. Although
the dose regimens of 13-cell toxin SZ for mice and rats
were not identical, in both rodent species, as already
reported (Lukid et al., 1991a; Luki et al., 1991b),
repeated injections with 5 subtoxic daily doses of SZ
induced delayed hyperglycemia 10 to 20 days after
completion of the treatment (Figure 1). In vivo treat-
ment of animals with 10 consecutive constant doses
(200 mg/kg/day) of PTX significantly reduces hyper-
glycemia in both experimental species. The protective
effect of the drug is long-lasting, at least for 8 weeks
after the end of the treatment when experiment was
terminated (Figure 1).
Cellular Changes
The interference of PTX with a pathological process
leading to islet dysfunction have further been studied
by immunological and immunohistochemical analysis
at the level of target tissue. Histological analysis and
comparison with untreated control was done by day 10
after the induction of the disease and completion of the
PTX treatment, and by day 56 of the monitoring of
hyperglycemia. In comparison to normal architecture
of the islets found in animals without any treatment, on
day 10 in control MLD-SZ-induced animals his-
topathological changes are evident. Analysis in some
of the islets of susceptible CBA/H mice at this time
revealed heavy mononuclear infiltrates (Figure 2). In
susceptible DA rats small infiltrates were rarely seen
(grade 1) and infiltrating cells were scattered through-
out the islets (Figure 3). In both species mononuclear
infiltration was accompanied with initial necrotic
changes and slight edema in the connective spaces
around the islets and blood vessels (Figures 2 and 3).
However, the majority of the islets were still well pre-
served and free from infiltration, thus suggesting asyn-
chronous process. Immunohistochemical analysis in
rats confirmed our earlier findings (Luki et al., 1991a)
that mononuclear cells participating in the insulitis
process were CD4+ and CD8+ lymphocytes, as well as
blood borne ED1+ macrophages. Some mononuclear
cells within the islets also were positively stained for
MHC ClassII. At the later stage of the disease (day 56)
most of the islets lost clear margins and their character-
istic structure. In both species progression of insulitis
led to more severe necrotic changes throughout the
affected islets (grade 2 prevailed), such as vacuoliza-
tion related to focal necrosis and picnosis of the islet
cells (data not shown). Treatment with PTX concomi-PENTOXIFYLLINE IN STREPTOZOTOCIN-INDUCED DIABETES 215
Plasma glucose (mmol/I)
14
12
10
3O
25
2O
15
10
0 7 14 21 28 35 42 49 56
Days
FIGURE Effects ofPTX treatment on the development of MLD-SZ-induced hyperglycemia in mice and rats. Plasma glucose levels, deter-
mined in CBA/H mice (A) and DA rats (B) receiving MLD-SZ for 5 consecutive days (o), or animals treated with MLD-SZ in conjunction
with PTX from day 0 to day 9 in relation to the first SZ injection (,). Significantly different from the value of MLD-SZ-treated but
non-PTX-treated control animals: *P<0.05; Student’s t-test
tantly with MLD-SZ significantly ameliorated his-
topathological changes and down-regulated influx of
inflammatory cells. In comparison with control
MLD-SZ-treated animals, on day 10 in both species
there were much larger numbers of normal islets
(grade 0), or islets with only mild mononuclear infil-216 STANISLAVA D. STOId-GRUJIId et al.
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FIGURE 2 Effect of PTX treatment on the development of MLD-SZ-induced insulitis in CBA/H mice. (A) Histology of pancreatic islet by
day 10 after MLD-SZ treatment (HE x 60). Note massive infiltration of the islet with the initial necrotic changes and endothelial swelling.
(B) Histology of pancreatic islet by day 10 after treatment with MLD-SZ + PTX (HE x 50). Note well preserved islets without insulitis and
necrosis and with normal endothel
trates (Figures 2 and 3). At this time, inflammatory
cells with the characteristic phenotype were virtually
absent, or rare and spread only to the periphery of the
islets (Figure 3). Vascular dilatation with hypertrophy
of the endothelium was hardly observed. In the later
period, in comparison to PTX nontreated diabetic ani-
mals, hypocellularity and atrophy of the islets were less
prominent and most of the islets still remained intact.
In general, although PTX prophylaxis could not com-
pletely suppress insulitis development and 13-cell dam-
age, it drastically reduced it severity, which was
sufficient for the normoglycemic status of the animals
(Figure 1).
Molecular Changes
To investigate the effects of PTX on the molecular
alterations accompanying islet destruction, we ana-
lyzed immunohystochemically the presence of proin-
flammator mediators (IFN-/ and iNOS) in the
islets. In control MLD-SZ-induced diabetic animals
mononuclear cell infiltration in pancreata was accom-
panied by prominent expression of IFN-7 and iNOS
(Figure 4). In addition to intraislet cells, marked
iNOS expression was observed on the endothelial
cells of the hypertrophic blood vessels. By contrast, in
the PTX-treated group, in some of the islets, rare
IFN-7
+ and iNOS+ cells were evenly dispersed
throughout, but most of the remaining islets were
completely negative (Figure 4), similarly to healthy
nontreated animals. Concordantly with diabetic sta-
tus, in MLD-SZ-treated animals impaired insulin
secretion was found, as revealed by insulin staining of
pancreata, while treatment with PTX resulted in unal-
tered distribution of insulin positive -cells
(Figure 4).PENTOXIFYLLINE IN STREPTOZOTOCIN-INDUCED DIABETES 217
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FIGURE 3 Effects ofPTX treatment on the MLD-SZ-induced cellular changes in rat pancreas on day 10, as revealed by immunohistochemi-
cal staining (PAP). Upper panels, Control DA rats treated with MLD-SZ only. Note diffuse infiltration of mononuclear cells and the initial
necrotic changes. Lower panels, DA rats treated with MLD-SZ + PTX. Note the absence of intrainsulitis with low degree of islet cell destruc-
tion. CD4 cells (W3/25 mAb), (A) mag. 120 and (E) mag. 120; CD8 cells (OX8 mAb), (B) mag. 120 and (F) mag. 120; ED1
blood-born macrophages (ED1 mAb), (C) mag. 180 and (G) mag. 180; MHC Class II cells (OX6 mAb), (D) mag. 180 and (H) mag.
120
DISCUSSION
In an attempt to elucidate the value of new drug regi-
mens in human disorders, a number of animal models
has been used with common molecular mechanisms
that are influenced by the compund tested. For
IDDM, widely accepted models similar to human dis-
ease are spontaneously developing diabetes in NOD
mice and BB rats. By using these models it has been
recently shown that PTX, and related compounds, rol-
ipram (Liang et al., 1998) and theophylline (Rabino-
vitch and Sumoski, 1990) may favorably influence
the course of the disease. However, multifactorial
process resulting in clinically overt diabetes may dif-
fer, depending on the experimental model used for the
study. In addition to genetic predisposition, various
exogenic factors, like infective agents (Chung et al.,
1997; Von Herrat et al., 1998.), dietary factors (Hel-
gasson and Jonasson, 1981; Borch-Johnsen et al.,
1984), or islet-specific toxins (Like and Rossini,
1976; Lenzen and Panten, 1988), may contribute to
the development of the disease. Therefore, in order to
examine immunomodulatory potential of PTX, we
used the priming of islets with -cell-specific toxin218 STANISLAVA D. STOId-GRUJIId et al.
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FIGURE 4 Effects of PTX treatment on the MLD-SZ-induced molecular changes in rat pancreas on day 10, as revealed by immunohisto-
chemical staining of pancreata. AP staining to insulin, mag. x 120 (A) and mag. x 60 (E); IFN-7 cells (DB1 mAb, PAP), mag. x 120 (B) and
mag. x 120 (F); iNOS cells (NO16 mAb, PAP), mag. x 120 (C), mag. x 180 (D) and mag. x 60 (G); Upper panels, Control DA rats treated
with MLD-SZ only. Note paucity of insulin-containing cells restricted to the central area of the islet, diffuse pattern of IFN-7 containing cells,
and homogenous pattern of iNOS-containing islet cells and endothelial cell layer. Lower panels, DA rats treated with MLD-SZ + PTX. Note
homogenous pattern of insulin-containing cells throughout the entire islet, and the absence of IFN-containing and iNOS-containing cells
SZ, in vivo the treatment leading to an immune medi-
ated inflammation and clinically overt diabetes. After
relatively short course of treatment with PTX, there
was a long-lasting protective effect both in suscepti-
ble CBA/H mice and DA rats. Although PTX prophy-
laxis could not completely suppress
MLD-SZ-induced mononuclear cell infiltration of the
islets, it drastically reduced its severity. It has been
recently shown that PTX inhibits ICAM-1 expression
in monocytes (Neuner et al., 1997) and the adhesion
of T lymphocytes to ICAM-1 and VCAM-1
(Gonzales-Amaro et al., 1998). On the other hand, it
has been shown in MLD-SZ-induced diabetic mice
that adhesion of lymphocytes to islet endothelium
depends on the expression of VCAM-1 and ICAM-1
in the pancreas (Ludwig et al., 1999). Therefore, it
seems that beneficial effect of PTX on
MLD-SZ-induced pathway of immune attack of
-cells may reside, at least in part, in its capacity to
interfere with the recruitment of immune and inflam-
matory cells from circulation. Indeed, we have shown
that PTX protects both mice and rats from develop-
ment of destructive intrainsulitis.
MLD-SZ-induced autoimmune diabetes appears to
be a T cell-dependent disease (Elliot et al., 1997).
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models of IDDM it has been postulated that the func-
tional state of APCs is responsible for the progression
of Thl-dependent destructive insulitis (Rothe and
Kolb, 1998). It appears that by stimulating Th cells
(Cockfield et al., 1989), MLD-SZ caused up-regula-
tion of IFN-y and MHC Class II expression that are
required to propagate the autoimmune process lead-
ing to IDDM. IFN-7 production can be reduced by
treatment with PTX (Figure 4 and Liang et al., 1998).
In addition, the spatial distribution ofMHC Class II
/
cells in control MLD-SZ-induced animals expressed
scattered pattern, while in PTX-treated animals Class
II
/ cells were found only in peri-insulitis (Figure 3).
Thus, according to our results, it seems that PTX may
influence the disease by down-regulating APCs.
In MLD-SZ induced autoimmune diabetes several
mechanisms have been implicated in the pathological
processes leading to -cell dysfunction and death,
including proinflammatory cytokine mediated induc-
tion of iNOS expression and NO production (Lukid et
al., 1991b; Lukid et al., 1998). Both exogenous NO
derived from nonendocrine islet cells (macrophages
or endothelial cells) and NO generated by the 13-cells
itself may contribute ,to tissue destruction (Corbett et
al., 1992; Kaneto et al., 1995; Corbett and McDaniel,
1995). Since PTX has been found to be able to inhibit
the release of inflammatory cytokines (Van-Furth et
al., 1994; Rieneck et al., 1995), and favor Th2
response (Liblau et al., 1995), the drug may indirectly
interfere with the induction of iNOS. It fits well with
the finding that PTX reduces deleterious effects of
TNF-ot on human islets (Ariasdiaz et al., 1995).
Recently we showed that PTX may have opposite
effects on iNOS expression in different cell types:
inhibitory in macrophages and enhancing in astro-
cytes (Trajkovi et al., 1997). Although the cellular
sources of iNOS in our experimental model may be
both endocrine and nonendocrine cells, in the present
study we showed that local expression of iNOS by
both intraislet cells and endothelial cells were reduced
after in vivo treatment with PTX. From this, it can be
concluded that another mechanism by which PTX
could exert its effect is by reducing NO-mediated
destruction of pancreatic -cells Whatever the cellular
source of NO is, interference with local NO produc-
tion by PTX could be relevant for autoimmune proc-
ess affecting the pancreas. However, the precise
mechanism of action on NO synthesis at the level of
NO-producing cells in the pancreas is at present not
known, but warrants further study.
MATERIALS AND METHODS
Animals
Genetically susceptible inbred male Dark Agouti (DA)
rats, and CBA/H mice were obtained from our own
breeding colony (Institute for Biological Research,
Belgrade, Yugoslavia), determined to be free from
common pathogens. Animals were used when 10 to 16
weeks old, and kept in groups of 5 to 6 per cage.
Induction of Diabetes and Drug Treatment
Diabetes was induced in two rodent species with mul-
tiple subtoxic doses of streptozotocin (SZ, S-0130,
Sigma, St Louis, MO), (20 mg/kg b. w./day in rats,
and 40 mg/kg b. w./day in mice), given i.p. for 5 con-
secutive days. Pentoxyfilline (PTX, Panfarma, Bel-
grade, Yugoslavia) was given i.m. at a dose of
200 mg/kg/day, from day 0 through day 9 in relation
to the induction of diabetes. Control, nontreated ani-
mals received injections of PBS. Plasma glucose was
determined by a glucose-oxidase method using a glu-
cometer (Glucotronic C; Macherey-Nagel, Duren,
Germany) once a week for up to 8 weeks. Clinical
diabetes was defined by hyperglycemia in nonfasted
animals (blood glucose > 11 mmol/1).
Histological and Immunohistochemical Analyses
of Pancreas
For histology, pancreata were prepared by embedding
in paraffin after fixing in formalin. To assess the inci-
dence of inflammatory changes, degree of islet cell
destruction and changes of connective tissue, histo-
logic sections (7 gm in thickness) were stained with
hematoxylin and eosin. Histological analysis was per-220 STANISLAVA D. STOgId-GRUJIId et al.
formed in a blind fashion by two observers. The
degree of inflammatory changes was graded accord-
ing to the following arbitrary scale: 0 intact islet
with no cellular infiltrates, 1 few infiltrated intrais-
let cells, but intact islet architecture, and 2- heavy
mononuclear infiltration with or without loss of islet
architecture. At least 5 animals per each experimental
group, and minimum 20 islets per animal were scored
individually.
Immunohistochemical analysis was performed
from a snap-frozen sections, using indirect immu-
noperoxidase staining as described previously
(Stoid-Grujiid et al., 1999). Staining of rat tissue
was performed using the following mouse anti-rat
mAbs: anti-CD4 (W3/25, Serotec, Oxford, England),
anti-CD8 (OX 8, Serotec), anti-IFN-y (DB 1, Holland
Biotechnology, Leiden, The Netherlands), anti-MHC
Class II (OX-6, Holland Biotechnology), and
anti-monocytes and macrophages (ED1, kindly pro-
vided by Dr. C. D. Dijskstra, Medical Faculty, Free
University, Amsterdam, The Netherlands). Rabbit
antiserum raised against a synthetic peptide corre-
sponding to the C-terminus of a long form of mouse
macrophage iNOS (NO16; kindly provided by Dr. C.
Nathan, Cornell University Medical College, NY),
cross-reactive with rat iNOS, was used for tissues of
both rodent species. Primary mAbs for mouse tissue
were as follows: rat anti-mouse CD4 (GK1.5) and
CD8 (YTS 169), both from Serotec, Oxford, and
anti-mouse interferon-gamma (IFN-y), (F3, Holland
Biotechnolgy). Staining to insulin was performed
with guinea pig anti-swine insulin primary antibody
(N 1542, Dako, Hamburg, Germany) using DAKO
LSAB Kit (K 0676, Dako) with alkaline phosphatase
(AP)-conjugated rabbit/mouse secondary antibody.
Statistical Analysis
Data were expressed as means + s.e.m. Student’s test
was used for evaluation statistical significance of dif-
ferences between groups. P-values were considered
significant at P< 0.05.
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